$671 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 103 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMCR | IMMUNOCORE HLDGS PLCads | $20,052,864 | -13.4% | 405,600 | 0.0% | 2.99% | -11.2% | |
| AXSM | AXSOME THERAPEUTICS INC | $19,737,600 | -20.0% | 320,000 | 0.0% | 2.94% | -18.0% | |
| BGNE | BEIGENE LTDsponsored adr | $18,320,050 | -2.0% | 85,000 | 0.0% | 2.73% | +0.5% | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $17,628,012 | -12.9% | 692,925 | 0.0% | 2.63% | -10.7% | |
| AZN | ASTRAZENECA PLCsponsored adr | $11,799,700 | +2.4% | 170,000 | 0.0% | 1.76% | +5.0% | |
| PCVX | VAXCYTE INC | $11,244,000 | -21.8% | 300,000 | 0.0% | 1.68% | -19.9% | |
| IONS | IONIS PHARMACEUTICALS INC | $7,148,000 | -5.4% | 200,000 | 0.0% | 1.06% | -2.9% | |
| KNSA | KINIKSA PHARMACEUTICALS LTD | $6,456,000 | -28.2% | 600,000 | 0.0% | 0.96% | -26.3% | |
| IMGN | IMMUNOGEN INC | $4,895,436 | -22.6% | 1,274,853 | 0.0% | 0.73% | -20.7% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $2,943,000 | -7.8% | 300,000 | 0.0% | 0.44% | -5.4% | |
| ITOS | ITEOS THERAPEUTICS INC | $2,949,287 | -30.3% | 216,700 | 0.0% | 0.44% | -28.6% | |
| AMYLYX PHARMACEUTICALS INC | $2,934,000 | -20.6% | 100,000 | 0.0% | 0.44% | -18.6% | ||
| INSM | INSMED INC | $2,833,761 | -14.7% | 166,203 | 0.0% | 0.42% | -12.4% | |
| RCUS | ARCUS BIOSCIENCES INC | $2,698,061 | -11.8% | 147,920 | 0.0% | 0.40% | -9.5% | |
| SBTX | ARS PHARMACEUTICALS INC | $2,665,604 | -23.7% | 409,463 | 0.0% | 0.40% | -21.7% | |
| 2SEVENTY BIO INC | $2,550,000 | +8.9% | 250,000 | 0.0% | 0.38% | +11.8% | ||
| ALLK | ALLAKOS INC | $1,993,453 | -47.1% | 447,967 | 0.0% | 0.30% | -45.8% | |
| BIOHAVEN LTD | $1,912,400 | -1.6% | 140,000 | 0.0% | 0.28% | +1.1% | ||
| LIFE | ATYR PHARMA INC | $259,203 | -4.1% | 123,430 | 0.0% | 0.04% | 0.0% | |
| ACELRX PHARMACEUTICALS INC | $128,310 | -70.9% | 195,000 | 0.0% | 0.02% | -70.3% | ||
| VINC | VINCERX PHARMA INC | $105,832 | +2.0% | 101,762 | 0.0% | 0.02% | +6.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.